Recent health news highlights include a landmark ruling by the Inter-American Court of Human Rights concerning abortion ...

The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late ...

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.16% higher to $397.27 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.09% ...

The FDA based its decision on laboratory evidence submitted by Vertex Pharmaceuticals that demonstrates these CFTR mutations ...

Vertex Pharmaceuticals said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of mutations of the ...

Desktop Metal, Inc. ("Desktop Metal") today announced that it has filed a lawsuit against Nano Dimension Ltd. ("Nano Dimension") in the Delaware Court of Chancery (the "Court"), alleging that Nano ...

这一消息直接来自Vertex Pharmaceuticals Incorporated，报告的签署人是公司执行副总裁兼首席法务官Jonathan Biller。FDA对ALYFTREK的批准是Vertex Pharmaceuticals的一个重要进展，可能会加强公司在囊性纤维化治疗领域的产品组合。

Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...

TRIKAFTA是elexacaftor、tezacaftor和ivacaftor的组合，旨在增强由囊性纤维化跨膜传导调节因子（CFTR）基因突变引起的缺陷蛋白的功能。FDA的批准包括至少有一个F508del突变或对TRIKAFTA有反应的突变的患者，这基于临床或体外数据。该药物的标签现在包括94个额外的非F508del CFTR突变。

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

William Pickering, an analyst from Bernstein, reiterated the Hold rating on Vertex Pharmaceuticals (VRTX – Research Report). The associated ...